In Vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1588-1590

  Wang, Chunfu ^a   Jia, Lingling ^a   Huang, Haichang ^a,c   Qiu, Dike ^a,b   Valera, Lourdes ^a   Huang, Xin ^b   Sun, Jin Hua ^a   Nower, Peter T ^a   O'Boyle II, Donald R ^a   Gao, Min ^a   Fridell, Robert A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BMS 90052; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG POTENCY; HEPATITIS C; HEPATITIS C VIRUS; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; GENES, REPORTER; GENOTYPE; HEPACIVIRUS; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; LUCIFERASES; MOLECULAR SEQUENCE DATA; REPLICON; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84863156581     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06169-11     Document Type: Article

References (10)

1. Combet C, et al. 2007. euHCVdb: the European hepatitis C virus database. Nucleic Acids Res. 35:D363-D366. (Pubitemid 46056232)
2. Fridell RA, et al. 2011. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J. Virol. 85:7312-7320.
3. Fridell RA, Qiu D, Wang C, Valera L, Gao M. 2010. Resistance analysis of the hepatitisCvirus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 54:3641-3650.
4. Fridell RA, et al. 2011. Genotypic and phenotypic analysis of variants resistant to hepatitisCvirus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 54:1924 -1935.
5. Gao M, et al. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96 -100.
6. Khattab MA, et al. 2011. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J. Hepatol. 54:1250-1262.
7. Lemm JA, et al. 2010. Identification of hepatitis C virus NS5A inhibitors. J. Virol. 84:482- 491.
8. Nettles RE, et al. 2011. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 54:1956 -1965.
9. O'Boyle DR, et al. 2005. Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob. Agents Chemother. 49:1346 -1353.
10. Simmonds P. 2004. Genetic diversity and evolution of hepatitis C virus - 15 years on. J. Gen. Virol. 85:3173-3188. (Pubitemid 39445434)